NeuroScientific Biopharmaceuticals Ltd. has been informed by the Human Research Ethics Committee (HREC) it rejected the Company's planned Phase I Clinical Trial for EmtinBTM. In making its decision, HREC determined that at this stage the supporting documentation did not sufficiently address the risk-benefit profile to justify the conduct of the planned Phase I Clinical Trial. The HREC decision to not approve the Phase I Clinical Trial was unexpected and the Company is seeking clarification on the rationale for the decision to determine what steps can be taken to proceed with the Phase I Clinical Trial.
NeuroScientific Biopharmaceuticals Limited
Equities
NSB
AU0000012973
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.045 AUD | 0.00% | -8.16% | +2.27% |
1st Jan change | Capi. | |
---|---|---|
+2.27% | 4.31M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- NSB Stock
- News NeuroScientific Biopharmaceuticals Limited
- Neuroscientific Biopharmaceuticals Ltd. Announces HREC Decision to Not Approve Phase I Clinical Trial